Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene

Blood

Volumn 100, Issue 3, 2002, Pages 1088-1091

  Magnusson, Magnus K ^a   Meade, Kristin E ^a   Nakamura, Ryotaro ^a   Barrett, John ^a   Dunbar, Cynthia E ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; IMATINIB; INTERLEUKIN 3; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ANIMAL CELL; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG TARGETING; FUSION GENE; GENETIC TRANSCRIPTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION;

EID: 0036682958     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0165     Document Type: Article

References (14)

1. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
2. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
3. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2)
4. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
5. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10) (q33;q22)
6. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia
7. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
8. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back
9. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: A common mechanism for transformation by tyrosine kinase fusion proteins
10. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells, expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
11. Chronic myeloproliferative diseases with t(5;12) and a PDGFRB fusion gene: Complete cytogenetic remissions on STI571
12. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
13. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways
14. Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein